MedPath

NUCALA

NUCALA

Approved
DIN Number

02530821

Drug Class

Human

Market Date

Feb 13, 2023

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02530821
AIG Number0157630001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  Prescription
A
ATC Code
R03DX09 MEPOLIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification90:28.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

MEPOLIZUMABActive
Strength: 40 MG / 0.4 ML
Monograph: MEPOLIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.